August 16th 2022
Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.
August 9th 2022
Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.
Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.
August 2nd 2022
Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.
A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.
July 26th 2022
Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.
Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.
July 19th 2022
Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.
Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice
July 12th 2022
Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.
Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.
July 5th 2022
Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.
A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.
June 28th 2022
A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.
Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.
February 7th 2022
Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.
September 20th 2021
Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.
October 28th 2020
Benjamin P. Levy, MD, discusses the mechanism of action of telaglenastat in non–small cell lung cancer.
September 28th 2020
Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.
September 25th 2020
Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.